Literature DB >> 7888224

A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.

M Purtscher1, A Trkola, G Gruber, A Buchacher, R Predl, F Steindl, C Tauer, R Berger, N Barrett, A Jungbauer.   

Abstract

We have established a hybridoma clone, designated 2F5, secreting a neutralizing human monoclonal antibody (MAb) specific for gp41 of human immunodeficiency virus type 1 (HIV-1). The epitope of MAb 2F5 was mapped to amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala on the ectodomain of gp41. In this study different in vitro test systems were used to characterize the neutralizing properties of MAb 2F5. In syncytium inhibition assays, fusion inhibition experiments, and neutralization assays on different HIV-susceptible cells (H9, U937, and peripheral blood mononuclear cells) MAb 2F5 showed broad-spectrum neutralizing capacity against HIV-1 laboratory isolates IIIB, MN, RF, and SF2. In addition, primary isolates from AIDS patients were also neutralized.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7888224     DOI: 10.1089/aid.1994.10.1651

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  161 in total

1.  Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins.

Authors:  Christoph Grundner; Tajib Mirzabekov; Joseph Sodroski; Richard Wyatt
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.

Authors:  J P Moore; P W Parren; D R Burton
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

5.  Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1.

Authors:  Robert Pejchal; Laura M Walker; Robyn L Stanfield; Sanjay K Phogat; Wayne C Koff; Pascal Poignard; Dennis R Burton; Ian A Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-02       Impact factor: 11.205

6.  Functional surfaces of the human immunodeficiency virus type 1 capsid protein.

Authors:  Uta K von Schwedler; Kirsten M Stray; Jennifer E Garrus; Wesley I Sundquist
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

7.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Infection of specific dendritic cells by CCR5-tropic human immunodeficiency virus type 1 promotes cell-mediated transmission of virus resistant to broadly neutralizing antibodies.

Authors:  Lakshmanan Ganesh; Kwanyee Leung; Karin Loré; Reuven Levin; Amos Panet; Owen Schwartz; Richard A Koup; Gary J Nabel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus.

Authors:  T Muster; B Ferko; A Klima; M Purtscher; A Trkola; P Schulz; A Grassauer; O G Engelhardt; A García-Sástre; P Palese
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.